Adjuvant immune checkpoint blockade revisited
- PMID: 37414008
- DOI: 10.1016/S1470-2045(23)00233-4
Adjuvant immune checkpoint blockade revisited
Conflict of interest statement
CB has received grants or contracts from Bristol Myers Squibb, Novartis, NanoString, and 4SC unrelated to this manuscript; consulting fees from or participation on an advisory board of Bristol Myers Squibb, MSD, Roche, Novartis, GlaxoSmithKline, AstraZeneca, Pfizer, Lilly, GenMab, Pierre Fabre, and Third Rock Ventures; is a co-founder of Immagene BV and Signature Oncology; and holds the following patents WO 2021/177822 A1, N2027907, P091040NL2 (from the Netherlands; on combination therapies comprising antibody molecules to PD-1, interleukin-2 gene signature, and a sensor for adrenocortical insufficiency). AH is on the advisory board of NFU-ZN quickscan. All other authors declare no competing interests.
Comment on
-
Cost per Event Averted in Cancer Trials in the Adjuvant Setting From 2018 to 2022.JAMA Netw Open. 2022 Jun 1;5(6):e2216058. doi: 10.1001/jamanetworkopen.2022.16058. JAMA Netw Open. 2022. PMID: 35687338 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources